177 related articles for article (PubMed ID: 30798670)
1. Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients.
Riccardi N; Del Puente F; Taramasso L; Di Biagio A
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821657. PubMed ID: 30798670
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
[No Abstract] [Full Text] [Related]
4. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
[TBL] [Abstract][Full Text] [Related]
6. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
8. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
Capetti AF; Sterrantino G; Cossu MV; Orofino G; Barbarini G; De Socio GV; Di Giambenedetto S; Di Biagio A; Celesia BM; Argenteri B; Rizzardini G
PLoS One; 2016; 11(10):e0164753. PubMed ID: 27741309
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
Capetti AF; Cossu MV; Sterrantino G; Barbarini G; Di Giambenedetto S; De Socio GV; Orofino G; Di Biagio A; Celesia BM; Rusconi S; Argenteri B; Rizzardini G
Ann Pharmacother; 2018 Aug; 52(8):740-746. PubMed ID: 29482352
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
Heredia A; Hassounah S; Medina-Moreno S; Zapata JC; Le NM; Han Y; Foulke JS; Davis C; Bryant J; Redfield RR; Wainberg MA
J Antimicrob Chemother; 2017 Sep; 72(9):2570-2573. PubMed ID: 28637235
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
14. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
15. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
16. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
[TBL] [Abstract][Full Text] [Related]
18. Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
Shafer RW
J Infect Dis; 2017 Dec; 216(suppl_9):S843-S846. PubMed ID: 28968669
[TBL] [Abstract][Full Text] [Related]
19. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
Capetti AF; Cossu MV; Paladini L; Rizzardini G
Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
